StreetInsider.com News Articles

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board

Tue, 05 May 2026 07:00:40 -0400

4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw

4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors